For over twenty years, a single study terrified an entire generation of women — and the doctors who cared for them. Hot flushes went untreated. Sleep was lost. Relationships suffered. Bones thinned quietly. And millions of women were told, with the best of intentions, that HRT — the treatment which could have helped them — was simply too dangerous to try.

That study was wrong. Not entirely, and not maliciously — but wrong in the ways that mattered most. And in January 2026, the FDA finally acknowledged what researchers have been saying for nearly a decade: it removed the black box warnings from menopausal hormone therapy labels, calling the old warnings inconsistent with current evidence.

This is not a story about a miracle drug. It’s a story about how one misread study shaped two decades of medical practice — and what we owe women now that the science has been corrected. Whether you’re a clinician re-evaluating your prescribing or a woman who was told HRT “wasn’t for you,” this guide covers what you need to know in 2026.

What Is HRT — and Why Was It Abandoned for 20 Years?

Hormone replacement therapy (HRT) — now more accurately called menopausal hormone therapy (MHT) — involves replacing the oestrogen and progesterone that the ovaries stop producing at menopause. It was widely prescribed throughout the 1980s and 1990s, not just for symptom relief, but because early observational data suggested it protected women’s hearts and bones.

Then came the Women’s Health Initiative (WHI) study in 2002. It was a large, randomised controlled trial — exactly the kind of evidence medicine should trust. And it showed that combined HRT (oestrogen plus progestin) was associated with increased risks of breast cancer, heart disease, stroke, and blood clots. The results were published. The headlines were catastrophic. Prescriptions collapsed almost overnight.

What nobody explained clearly at the time was that the WHI studied a very specific group of women: average age 63, the majority more than 10 years past menopause, many with pre-existing cardiovascular risk factors. These were not the women who typically needed or sought HRT. The results, applied universally, led to a generation of under-treatment.

What the Evidence Actually Shows in 2026

The reassessment of HRT evidence over the past decade has been one of the most significant reversals in women’s medicine. Here are the numbers that every clinician and patient should know.

“For most healthy, symptomatic women under 60 who are within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks.” — Korean Society of Menopause Guidelines, 2025

The Breast Cancer Question — Putting the Risk in Context

This is the fear that stopped prescribing for two decades. Let’s address it directly, because the numbers are routinely misunderstood — by patients and clinicians alike.

For combined HRT using synthetic progestin: the relative risk increase of breast cancer is approximately 26% in long-term users (5+ years). That sounds alarming. But relative risk numbers mean nothing without the baseline. For a 50-year-old woman, the absolute background risk of breast cancer is roughly 2 in 100 over 5 years. A 26% relative increase brings that to approximately 2.5 in 100 — an absolute increase of 0.5 women per 100.

Oestrogen-Only HRT and Breast Cancer

For women who have had a hysterectomy and take oestrogen alone, the evidence is reassuring. The WHI oestrogen-only arm was actually stopped early because oestrogen alone showed a trend toward reduced breast cancer incidence. Oestrogen-only HRT is not associated with an increased risk of breast cancer — and emerging data suggest it may be protective.

Route Matters as Much as Dose — Transdermal vs. Oral

This is the part of the HRT conversation that most online resources still get wrong. The way oestrogen is delivered into the body dramatically changes its risk profile — particularly for blood clots and stroke.

The clinical implication is clear: for women with risk factors for VTE — obesity, personal or family history of clots, long-haul travel — transdermal oestrogen is the preferred route. Oral preparations are not contraindicated in low-risk women, but transdermal is safer when in doubt.

Who Should and Should Not Take HRT — A Clinical Framework

Common Mistakes Doctors Make When Prescribing HRT in 2026

A Note for Patients

If you’ve been living with hot flushes, broken sleep, brain fog, joint pain, or mood changes and told yourself “it’s just menopause, I’ll manage” — you don’t have to. These symptoms are real, they are treatable, and the treatment is now considered safe for the majority of women when started at the right time.

The fear surrounding HRT came from one large study, and that study has now been substantially reanalysed and recontextualised. The FDA removed its most serious warning label in early 2026. Leading menopause societies worldwide — including the British Menopause Society, the North American Menopause Society, and the International Menopause Society — all support HRT for symptomatic women under 60 who have no specific contraindications.

The most important thing you can do is have an honest conversation with your doctor. Bring your symptom history, your family medical history, and your questions. HRT is not right for every woman — but it deserves to be part of the conversation for far more women than it currently reaches.

Summary

• The 2002 WHI study caused two decades of HRT under-prescribing — based on a misapplication of data from older, higher-risk women to all women.
• In January 2026, the FDA removed black box warnings from menopausal hormone therapy labels, reflecting updated evidence.
• HRT started within 10 years of menopause (the “timing window”) reduces total mortality by 30% and cardiovascular mortality by 48%.
• Oestrogen-only HRT does not increase breast cancer risk; combined HRT with micronised progesterone carries a lower risk than older synthetic progestins.
• Transdermal oestrogen does not increase VTE or stroke risk — it is the preferred route for women with relevant risk factors.
• Local vaginal oestrogen is safe for nearly all women and should not be withheld without clear reason.
• Contraindications include oestrogen-receptor positive breast cancer, active VTE, active cardiovascular disease, and unexplained vaginal bleeding.
• The decision should always be individualised — benefits and risks vary significantly between patients.

References

1. Rossouw JE, et al. Risks and Benefits of Oestrogen Plus Progestin in Healthy Postmenopausal Women (WHI). JAMA. 2002;288(3):321–333.
2. Manson JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality. JAMA. 2017;318(10):927–938.
3. Kim SH, et al. The 2025 Menopausal Hormone Therapy Guidelines — Korean Society of Menopause. Journal of Menopausal Medicine. 2025; PMC12438153.
4. US Food and Drug Administration. Updated Labeling for Menopausal Hormone Therapy. JAMA. 2026 Jan. jamanetwork.com/journals/jama/fullarticle/2841321.
5. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk. Lancet. 2019;394(10204):1159–1168.
6. Schierbeck LL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409.
7. Vinogradova Y, et al. Use of hormone replacement therapy and risk of venous thromboembolism. BMJ. 2019;364:k4810.
8. The Lancet Diabetes & Endocrinology. Is it time to revisit the recommendations for initiation of menopausal hormone therapy? Lancet Diab Endocrinol. 2024; PIIS2213-8587(24)00270-5.
9. North American Menopause Society (NAMS). Hormone Therapy Position Statement. 2022 Update. menopause.org.
10. British Menopause Society. HRT — Benefits and Risks. BMS Clinical Guidance. 2024 Update. thebms.org.uk.